Repligen Corporation (RGEN : NASDAQ)
Common Stock
$177.23
USD
-15.00 (-7.80%)
Last updated: 2026-10-01
Follow RGEN
RGEN
Repligen Corporation
WealthAwesomePerformance
1 Day
-7.80%
1 Week
-7.04%
1 Month
+4.24%
YTD
+32.71%
Key Statistics
Market Cap
$10.00B
52W High
$198.87
52W Low
$100.99
P/E Ratio
264.52
50 Day MA
$168.78
200 Day MA
$143.40
Beta
1.05
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/1/2026 | $194.00 | $194.00 | $177.12 | $177.23 | $177.23 | 1,945,821 |
| 9/30/2026 | $193.09 | $195.61 | $190.97 | $192.23 | $192.23 | 730,393 |
| 9/29/2026 | $196.00 | $196.65 | $190.98 | $194.57 | $194.57 | 1,135,004 |
| 9/28/2026 | $187.25 | $198.87 | $187.11 | $194.09 | $194.09 | 1,567,142 |
| 9/25/2026 | $189.92 | $191.51 | $186.91 | $189.68 | $189.68 | 1,502,400 |
| 9/24/2026 | $184.10 | $192.49 | $183.75 | $190.65 | $190.65 | 1,602,615 |
| 9/23/2026 | $186.38 | $188.94 | $181.71 | $184.53 | $184.53 | 934,768 |
| 9/22/2026 | $180.72 | $188.20 | $180.00 | $186.75 | $186.75 | 1,159,791 |
| 9/21/2026 | $176.89 | $182.25 | $176.22 | $180.71 | $180.71 | 857,648 |
| 9/18/2026 | $179.10 | $179.10 | $176.29 | $176.89 | $176.89 | 1,359,700 |
Analyst Price Targets
Based on 19 analysts covering RGEN · as of Oct 1, 2026
Wall Street analysts forecast RGEN stock price to rise 7.0% over the next 12 months.
Consensus
Buy4.26 / 5.00
Avg. Target
US$189.70
+7.0% Upside
Previously US$189.48 on Sep 21, 2026
Current Price
US$177.23
Last close
Analyst Breakdown (19 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RGEN's historical volatility
30-Day Vol
42.2%
Annualized
90-Day Vol
49.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$211.88
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$188.10 | US$162.59 – US$217.61 |
| 60 trading days | US$199.64 | US$162.45 – US$245.33 |
| 90 trading days | US$211.88 | US$164.61 – US$272.73 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Financials
- Revenue (TTM)
- $785.10M
- EBITDA
- $144.10M
- Profit Margin
- 5.29%
- ROE (TTM)
- 1.99%
- EPS (Diluted)
- 0.67
- Book Value
- 37.43
Classification
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About RGEN.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| IFRX | InflaRx N.V. | $145.00 | +7955.56% |
| BGM | Qilian International Holding Group Limited | $7.82 | +3005.64% |
| KUST | Kustom Entertainment, Inc. | $4.42 | +944.42% |
| SSM | Sono Group N.V. | $2.21 | +97.32% |
| NXL | Nexalin Technology Inc. | $7.55 | +76.40% |
| VEEA | Veea Inc. | $3.47 | +59.91% |
| RPGL | Republic Power Group Limited Class A Ordinary Shares | $26.20 | +59.85% |
| XRPN | Armada Acquisition Corp. II | $23.43 | +42.87% |
RGEN.US news timeline
1 article covering RGEN.US, most recent first
Latest